Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

Cell-free DNA purification upgrade, 3/16

March 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multi-template analysis LiquidBiopsy platform.

NGS HLA typing solution, 3/16

March 2016—Immucor, in collaboration with Sirona Genomics, announced the launch of Mia Fora NGS, a high-resolution human leukocyte antigen typing solution that provides accurate, comprehensive coverage of 11 HLA genes. With a workflow that can be automated or run manually, Mia Fora NGS is adapted for use on the Illumina MiSeq next-generation sequencing platform and is available for research use only in the U.S. and other countries, with CE mark anticipated shortly.

Chembio to sell its Sure Check HIV 1/2 Assay, 3/16

March 2016—Chembio Diagnostics will begin selling its Sure Check HIV 1/2 Assay in the U.S. market on June 1. The product is currently distributed in the United States by Alere under Alere’s Clearview Complete brand, and Chembio has notified Alere that it will not renew or extend the distribution agreement when it terminates on May 31.

High-capacity FISH hybridization system, 3/16

March 2016—SciGene introduced a high-capacity system for performing FISH hybridization assays. The system consists of one CytoBrite Slide Incubation System for performing rapid probe denaturation on batches of 12 FISH slides and one CytoBrite Slide Oven for overnight hybridizations of 60 slides. Removable slide trays streamline slide setup and transfers between instruments.

Sakura Finetek acquires Genemed, 3/16

March 2016—Sakura Finetek USA announced the acquisition of Genemed Biotechnologies’ tissue-based advanced staining business for cancer detection, diagnosis, and monitoring. Genemed’s liquid-based molecular testing products were not included in the acquisition and will be spun out as an independent business.

Multiplex TTF-1 and cytokeratin 5 cocktail, 3/16

March 2016—ScyTek Laboratories announced the availability of its Multiplex TTF-1 and Cytokeratin 5 Cocktail. This multiplex cocktail of TTF-1 and cytokeratin 5 produces two-color, high-contrast staining for differentiating primary adenocarcinoma of the lung from metastatic carcinomas of the breast and malignant mesothelioma. This cocktail can increase sensitivity and diagnostic utility in differential diagnosis of the tumor.

PerkinElmer acquires Vanadis, 3/16

March 2016—PerkinElmer has acquired Vanadis Diagnostics. Based in Sweden, Vanadis is developing a novel solution for non-invasive prenatal testing based on digital analysis of cell-free DNA.

Image analysis software, 3/16

March 2016—Definiens released its Tissue Studio 4.2 software package. The updated product suites provide improved image analysis functionality for scientists in academic medical centers, comprehensive cancer centers, and biotech and pharmaceutical companies.

CE marking for pneumonia FIA, 3/16

March 2016—Quidel has received the CE mark for its Sofia S. pneumoniae fluorescent immunoassay for use with the Sofia Fluorescent Immunoassay Analyzer. The Sofia S. pneumoniae FIA enables the qualitative detection of Streptococcus pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid of patients with meningitis in 10 minutes.

NanoString collaboration with Medivation, Astellas, 3/16

March 2016—Medivation and NanoString Technologies have entered into a collaboration, together with Astellas Pharma, to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString’s nCounter Dx Analysis System.